386 related articles for article (PubMed ID: 11697753)
1. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.
Buckwalter M; Dowell JA; Korth-Bradley J; Gorovits B; Mayer PR
J Clin Pharmacol; 2004 Aug; 44(8):873-80. PubMed ID: 15286091
[TBL] [Abstract][Full Text] [Related]
3. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
4. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
Shannon-Dorcy K
Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
[TBL] [Abstract][Full Text] [Related]
6. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
Larson RA; Boogaerts M; Estey E; Karanes C; Stadtmauer EA; Sievers EL; Mineur P; Bennett JM; Berger MS; Eten CB; Munteanu M; Loken MR; Van Dongen JJ; Bernstein ID; Appelbaum FR;
Leukemia; 2002 Sep; 16(9):1627-36. PubMed ID: 12200674
[TBL] [Abstract][Full Text] [Related]
7. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse.
Sievers EL
Expert Opin Biol Ther; 2001 Sep; 1(5):893-901. PubMed ID: 11728223
[TBL] [Abstract][Full Text] [Related]
9. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
10. New developments in antibody therapy for acute myeloid leukemia.
Tomblyn MR; Tallman MS
Semin Oncol; 2003 Aug; 30(4):502-8. PubMed ID: 12939719
[TBL] [Abstract][Full Text] [Related]
11. The role of gemtuzumab ozogamicin in acute leukaemia therapy.
Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM
Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia.
Hibma J; Knight B
Clin Pharmacokinet; 2019 Mar; 58(3):335-347. PubMed ID: 30062662
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
14. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
van Der Velden VH; te Marvelde JG; Hoogeveen PG; Bernstein ID; Houtsmuller AB; Berger MS; van Dongen JJ
Blood; 2001 May; 97(10):3197-204. PubMed ID: 11342449
[TBL] [Abstract][Full Text] [Related]
15. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR
Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
Kobayashi Y; Tobinai K; Takeshita A; Naito K; Asai O; Dobashi N; Furusawa S; Saito K; Mitani K; Morishima Y; Ogura M; Yoshiba F; Hotta T; Bessho M; Matsuda S; Takeuchi J; Miyawaki S; Naoe T; Usui N; Ohno R
Int J Hematol; 2009 May; 89(4):460-469. PubMed ID: 19360457
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Giles F; Estey E; O'Brien S
Cancer; 2003 Nov; 98(10):2095-104. PubMed ID: 14601078
[TBL] [Abstract][Full Text] [Related]
18. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.
Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):40-6. PubMed ID: 11792177
[TBL] [Abstract][Full Text] [Related]
19. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.
Duong HK; Sekeres MA
Clin Interv Aging; 2009; 4():197-205. PubMed ID: 19503782
[TBL] [Abstract][Full Text] [Related]
20. Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin.
Korth-Bradley JM; Dowell JA; King SP; Liu H; Berger MS;
Pharmacotherapy; 2001 Oct; 21(10):1175-80. PubMed ID: 11601662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]